HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Glaxo Wellcome

  • News

Executive Summary

Glaxo Wellcome: Closing of prescription manufacturing operations in Greenville, N.C. facility is announced July 25 by the company. Prescription manufacturing will be centered in Zebulon, N.C., as Rx operations in Greenville are phased out over the next five years with approximately 1,000 positions to be eliminated. Greenville facility will continue to manufacture over-the-counter products. Glaxo's partially renovated Kenly, N.C. plant is up for sale...

Glaxo Wellcome: Closing of prescription manufacturing operations in Greenville, N.C. facility is announced July 25 by the company. Prescription manufacturing will be centered in Zebulon, N.C., as Rx operations in Greenville are phased out over the next five years with approximately 1,000 positions to be eliminated. Greenville facility will continue to manufacture over-the-counter products. Glaxo's partially renovated Kenly, N.C. plant is up for sale....
Table

View full table

Tags:
Latest Headlines

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

Probiotics And Cold Remedies Boost Recordati In 2023

See All
UsernamePublicRestriction

Register

PS026636

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By